Clinical trial · Observational
ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa
NCT06200558CI-TRIAL-00097980recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Study wants to explore real-world data in three distinct settings * Patients with metachronous or de novo mCSPC treated with ADT+ARSI or ADT+ARSI+docetaxel \_ARON-3S * Patients receiving Lutetium-177 PSMA for mCRPC \_ ARON-3Lu * Patients treated with PARP inhibitors (alone or combined with ARSI) for CRPC \_ ARON-3GEN
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (3)
- label
- For ARON-3S: Patients with metachronous or de novo metastatic hormone/castration-sensitive PCa
- description
- Patients with metachronous or de novo metastatic hormone/castration-sensitive PCa treated with ADT+ARSI or ADT+ARSI+docetaxel
- label
- For ARON-3Lu: Patients receiving Lutetium-177 PSMA for castration resistant PC (CRPC)
- label
- For ARON-3GEN: Patients treated with PARP inhibitors (alone or plus ARSI) for CRPC
Primary outcomes (9)
- measure
- Overall Survival (OS) of patients with hormone/castration-sensitive PC treated with ADT + ARSI or ADT + ARSI + docetaxel
- timeFrame
- January 31h, 2024- May 31th, 2024
- measure
- Progression-Free Survival of patients with hormone/castration-sensitive PC treated with ADT + ARSI or ADT + ARSI + docetaxel
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged \>18y * Cytological or Histologically confirmed diagnosis of PC * Histologically or radiologically confirmed diagnosis of metastatic disease and For ARON-3S ▪ Treatment with ADT + Apalutamide or ADT + enzalutamide or ADT + Abiraterone or ADT + Abiraterone + Docetaxel or ADT + Darolutamide + Docetaxel (patients treated with previous docetaxel - CHAARTED - resulted eligible) For ARON-3Lu ▪ Treatment with Luthetium-177-PSMA therapy for castration resistant PC For ARON-3GEN * HRD POSITIVE STATUS * Treatment with PARP inhibitors for castration resistant PC. Treatment included: olaparib (as 1st, 2nd or 3rd line therapy), olaparib + abiraterone (as 1st line therapy) or niraparib + abiraterone (as 1st line therapy) or talazoparib + enzalutamide Exclusion Criteria: * Patients without histologically confirmed diagnosis of PC * Patients without histologically or radiologically confirmed metastatic disease and For ARON-3S ▪ Patients treated with doublets or triplets not included in the list reported in the Inclusion Criteria Section For ARON-3Lu ▪ Patients treated with Luthetium-177-PSMA therapy for hormone/castration sensitive PC For ARON-3GEN * HRD NEGATIVE STATUS * Patients treated with PARP inhibitors alone or in combination regimens not included in the ARON-3GEN study
References
Publications (0)
Data not yet available
No reference posted for this study.